Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry
European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5994-5998
DOI: 10.1007/s00259-026-07948-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.05.2026. Verfasst von Marnix Lam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, P.O. Box 85500, Utrecht, 3508 GA, The Netherlands. m.lam@umcutrecht.…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Radioembolization, Therapeutic. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
EPOCH demonstrated superior progression free survival using yttrium-90 [ 90 Y] glass microspheres radioembolization plus chemotherapy versus chemotherapy in colorectal cancer patients with liver metastases who had progressed following first-line oxaliplatin or irinotecan-based chemotherapy. Exploratory post-hoc analyses and theoretical modeling assessed the potential impact of dosimetry on safety outcomes. Patients and methods Liver-related treatment-emergent adverse event (TEAE) frequency and/or severity, and bilirubin increase were explored in participating patients. For hypothesis generation, a theoretical model was constructed to understand EPOCH dosimetry in the absence of multicompartment dosimetry data.
Results
Liver-related TEAEs were reported in 93/186 (50%) patients, TEAEs ≥ grade 3 in 44/186 (24%) patients. A total of 26/186 patients (14%) experienced a bilirubin increase TEAE of any grade, in five of which assessed as related to glass [ 90 Y]Y-radioembolization with a median fractional tumour involvement of 2.3% (range 1.4–4.1%). Under the theoretical assumption of a T/N ratio of 2–10, most patients in EPOCH (62% had a fractional tumour involvement < 10%) received a normal liver absorbed dose of at least 75 Gy. In this model, at < 4.1% fractional tumour involvement, the normal liver absorbed dose approximates 120 Gy at any T/N ratio.
Conclusion
When treatment is same-day whole liver at 120 Gy average absorbed dose, the normal liver absorbed dose is dependent on fractional tumour involvement. Trial Registration ClinicalTrials.gov NCT01483027.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, P.O. Box 85500, Utrecht, 3508 GA, The Netherlands. m.lam@umcutrecht.nl.
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
- Division of Hematology and Oncology, University of Washington, Seattle, WA, USA.
- Boston Scientific Corporation, Marlborough, MA, USA.
- Department of Nuclear Medicine, Cancer Institute Eugene Marquis, Rennes, France.
- Department of Radiology, Northwestern University, Chicago, IL, USA.
ORCID-Profile: Marnix Lam
Zitieren
APA
Lam, M., Kersting, D., Harris, W., Boucher, E., Garin, E., Fowers, K., & Salem, R. (2026). Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5994-5998. https://doi.org/10.1007/s00259-026-07948-6
Vancouver
Lam M, Kersting D, Harris W, Boucher E, Garin E, Fowers K, et al. Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5994-5998. doi:10.1007/s00259-026-07948-6
BibTeX
@article{Lam2026,
author = {Lam, Marnix and Kersting, David and Harris, William and Boucher, Eveline and Garin, Etienne and Fowers, Kirk and Salem, Riad},
title = {Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {10},
pages = {5994--5998},
doi = {10.1007/s00259-026-07948-6}
}
EUVIMED